How are CYP2C19 and Allergie related?

The relationship between CYP2C19 and allergies is indirect and primarily pharmacogenetic. CYP2C19 is a cytochrome P450 enzyme that metabolizes many drugs, including some antihistamines and proton pump inhibitors (PPIs) used in allergic conditions like urticaria or reflux. Genetic variants (e.g., *2, *3, *17) alter enzyme activity: poor metabolizers have reduced function, ultrarapid metabolizers increased function. This can affect the efficacy and tolerability of drugs such as desloratadine (antihistamine) or omeprazole. However, there is no strong evidence that CYP2C19 variants directly influence allergy risk or the immune response to allergens. The association is largely mechanistic and limited to drug metabolism. Direct-to-consumer DNA tests often overstate the clinical significance of such variants. For allergy diagnosis, specific IgE tests and clinical evaluation remain essential, not CYP2C19 genotyping.